Login
$ASND
$260.02 -$15.37 (5.58%) Live

Company Executives

Officer Age In this role Source
Jan Møller Mikkelsen Also a director
President, Chief Executive Officer and Board Member
66 Since 2007
19 years
Scott T. Smith
Executive Vice President, Chief Financial Officer
52 Since 2023
3 years
Jethro Ekuta
Chief Regulatory & Safety Officer
62 Since 2024
2 years
Sherrie Glass
Chief Business Officer
54 Since 2024
2 years
Michael Wolff Jensen
Executive Vice President, Chief Legal Officer
54 Since 2023
3 years
Lotte Sønderbjerg
Executive Vice President, Chief Administrative Officer
64 Since 2023
3 years
Aimee Shu
Executive Vice President, Chief Medical Officer
49 Since 2024
2 years
Anni Lotte Kirstine Sonderbjerg Pedersen
EVP & Chief Admin Officer
Title from the Form 3 dated Mar 18, 2026
Not stated Not stated
Jay Donovan Wu
EVP & President US Market
Title from the Form 3 dated Mar 18, 2026
40 Not stated
Stina Singel
Executive Vice President, Head of Clinical Development, Oncology
52 Since 2023
3 years
Mads Bodenhoff
SVP & PAO
Title from the Form 4 dated Sep 8, 2026
57 Not stated
Flemming Steen Jensen
See Remarks
Title from the Form 4 dated May 11, 2026
64 Not stated
Kennett Sprogøe
See Remarks
Title from the Form 3 dated Mar 18, 2026
47 Not stated

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the 20-F annual report

Directors
6
serving now
Independent
5 of 5
stated in the proxy; 1 not stated
Average tenure
7.4 years
from year joined
CEO also chairs the board
No
Albert Cha
Director Age On board Independent Committees Pay Source
Albert Cha
53 2014
12 years
Independent
Remuneration Committee · Chair Nominating and Corporate Governance Committee · Chair
Not stated
Jan Møller Mikkelsen
66 Not stated Not stated None stated Paid as CEO
Lisa Bright
58 2017
9 years
Independent
Audit Committee Remuneration Committee Nominating and Corporate Governance Committee
Not stated
William Carl Fairey Jr.
61 2022
4 years
Independent
Audit Committee
Not stated
Lars Holtug
67 2018
8 years
Independent
Audit Committee · Chair Remuneration Committee
Not stated
Siham Imani
48 2022
4 years
Independent
Nominating and Corporate Governance Committee
Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No proxy statement on record

Related-party transactions come from the company’s proxy statement. Ascendis Pharma A/S has not filed one with the SEC.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support